About G1 Therapeutics (NASDAQ:GTHX)
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835
Debt
Debt-to-Equity RatioN/A
Current Ratio8.95%
Quick Ratio8.95%
Price-To-Earnings
Trailing P/E Ratio-10.90
Forward P/E Ratio-15.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$520,000.00
Price / Sales2,447.35
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book11.83
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees44
Outstanding Shares32,690,000
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics (NASDAQ:GTHX) issued its earnings results on Wednesday, February, 21st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.02. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
5 brokerages have issued 12-month price targets for G1 Therapeutics' stock. Their predictions range from $31.00 to $48.00. On average, they expect G1 Therapeutics' stock price to reach $38.20 in the next twelve months. View Analyst Ratings for G1 Therapeutics.
What are Wall Street analysts saying about G1 Therapeutics stock?
Here are some recent quotes from research analysts about G1 Therapeutics stock:
- 1. BTIG Research analysts commented, "On Monday before market open, G1 announced positive topline data from the Phase 2a study of trilaciclib in combination with etoposide + carboplatin for patients with Extensive-stage SCLC (1st Line). We think that the Phase 2a study hit the important safety endpoints and set the company up well for later-line data with SCLC and metastatic Triple Negative Breast Cancer expected during 2H2018. Importantly, mgmt. indicated that they would use the strength of the 1st Line SCLC Phase2a data to begin discussions with regulators, which could accelerate the timeline versus awaiting data from the other studies during 2H2018. We reiterate our Buy rating and raise our PT to $48 from $38 as the topline release de-risks our assumptions around SCLC." (3/7/2018)
- 2. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (2/26/2018)
- 3. Cowen Inc analysts commented, "G1 Therapeutics reported a Q3 net loss of $16MM and September 30 cash of." (11/8/2017)
Are investors shorting G1 Therapeutics?
G1 Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totalling 1,658,179 shares, an increase of 71.8% from the February 28th total of 965,323 shares. Based on an average daily volume of 520,076 shares, the short-interest ratio is presently 3.2 days. Currently, 10.4% of the company's stock are sold short.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD), Akorn (AKRX), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT) and Cambrex (CBM).
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 54)
- Dr. Rajesh K. Malik, Chief Medical Officer (Age 59)
- Mr. Barclay A. Phillips, CFO & Sr. VP of Corp. Devel. (Age 55)
- Ms. Jennifer K. Moses, VP of Fin. & Admin. & Principal Accounting Officer (Age 43)
- Mr. Alexander D. Smith M.S., VP of Technical Operations
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Has G1 Therapeutics been receiving favorable news coverage?
Media stories about GTHX stock have trended somewhat negative recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. G1 Therapeutics earned a media sentiment score of -0.02 on Accern's scale. They also assigned press coverage about the company an impact score of 46.38 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $38.93.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $1.27 billion and generates $520,000.00 in revenue each year. The company earns $-60,120,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. G1 Therapeutics employs 44 workers across the globe.
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
G1 Therapeutics (NASDAQ:GTHX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for G1 Therapeutics in the last 12 months. Their average twelve-month price target is $38.20, suggesting that the stock has a possible downside of 1.88%. The high price target for GTHX is $48.00 and the low price target for GTHX is $31.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $38.20 | $38.20 | $31.40 | $29.75 |
| Price Target Upside: | 1.88% downside | 7.45% upside | 63.12% upside | 137.43% upside |
G1 Therapeutics (NASDAQ:GTHX) Consensus Price Target History
G1 Therapeutics (NASDAQ:GTHX) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
G1 Therapeutics (NASDAQ:GTHX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
G1 Therapeutics (NASDAQ GTHX) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 42.10%
G1 Therapeutics (NASDAQ GTHX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Mark A Velleca | Insider | Sell | 7,500 | $36.00 | $270,000.00 | |  |
| 4/5/2018 | Jennifer K Moses | VP | Sell | 750 | $37.47 | $28,102.50 | | |
| 3/15/2018 | Rajesh Malik | Insider | Sell | 3,776 | $38.18 | $144,167.68 | | |
| 3/5/2018 | Jennifer K Moses | VP | Sell | 750 | $26.55 | $19,912.50 | | |
| 2/15/2018 | Rajesh Malik | Insider | Sell | 3,776 | $20.00 | $75,520.00 | | |
| 2/5/2018 | Jennifer K Moses | VP | Sell | 750 | $22.99 | $17,242.50 | | |
| 1/16/2018 | Rajesh Malik | Insider | Sell | 3,776 | $22.96 | $86,696.96 | | |
| 1/5/2018 | Jennifer K Moses | VP | Sell | 750 | $19.96 | $14,970.00 | | |
| 12/18/2017 | Mark A Velleca | Insider | Sell | 7,500 | $20.01 | $150,075.00 | | |
| 12/15/2017 | Medimmune Ventures, Inc. | Major Shareholder | Sell | 200,000 | $19.75 | $3,950,000.00 | | |
| 12/1/2017 | Medimmune Ventures, Inc. | Major Shareholder | Sell | 133,906 | $19.75 | $2,644,643.50 | | |
| 11/20/2017 | Medimmune Ventures, Inc. | Major Shareholder | Sell | 200,000 | $20.01 | $4,002,000.00 | | |
| 11/13/2017 | Fredric N Eshelman | Director | Buy | 250,000 | $19.73 | $4,932,500.00 | | |
| 5/22/2017 | Clay Thorp | Major Shareholder | Buy | 133,333 | $15.00 | $1,999,995.00 | | |
| 5/22/2017 | Fredric N Eshelman | Director | Buy | 300,000 | $15.00 | $4,500,000.00 | | |
| 5/22/2017 | Ra Capital Healthcare Fund Lp | Insider | Buy | 400,000 | $15.00 | $6,000,000.00 | | |
(Data available from 1/1/2013 forward)
G1 Therapeutics (NASDAQ GTHX) News Headlines
| Source: |
|
G1 Therapeutics (NASDAQ:GTHX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
G1 Therapeutics (NASDAQ:GTHX) Income Statement, Balance Sheet and Cash Flow Statement
G1 Therapeutics (NASDAQ GTHX) Stock Chart for Sunday, April, 22, 2018
Loading chart…
